These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3653502)

  • 1. Effects of intravenous erythromycin lactobionate in respiratory infections.
    Di Sciacca A; Durante F; Cucchiara G; Ingrassia A; Mira G; Mannone F; Di Piazza RM; Frontini A; Barbagallo Sangiorgi G
    J Int Med Res; 1987; 15(4):245-50. PubMed ID: 3653502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulminant hepatic failure associated with intravenous erythromycin lactobionate.
    Gholson CF; Warren GH
    Arch Intern Med; 1990 Jan; 150(1):215-6. PubMed ID: 2297290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pharmacokinetics of 1,000 mg erythromycin lactobionate i. v. in patients with respiratory tract infections (author's transl)].
    Sietzen W
    Infection; 1982; 10 Suppl 2():S99-101. PubMed ID: 7107025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous erythromycin lactobionate-induced severe nausea and vomiting.
    Seifert CF; Swaney RJ; Bellanger-McCleery RA
    DICP; 1989 Jan; 23(1):40-4. PubMed ID: 2655295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two oral forms of erythromycin in the treatment of acute respiratory tract infections. A multicentre general practice study.
    Macklin J; Barden R; Coles S
    J Int Med Res; 1989; 17(3):287-94. PubMed ID: 2670633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of serum levels, venous irritation and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infection.
    Marlin GE; Thompson PJ; Jenkins CR; Burgess KR; LaFranier DA
    Hum Toxicol; 1983 Oct; 2(4):593-605. PubMed ID: 6642516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate.
    Karmody CS; Weinstein L
    Ann Otol Rhinol Laryngol; 1977; 86(1 Pt 1):9-11. PubMed ID: 835977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenous erythromycin lactobionate.
    Parsons RL; David JA; Raymond K; Stamp SM
    J Int Med Res; 1980; 8 Suppl 2():15-23. PubMed ID: 6968696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythromycin lactobionate: pharmacokinetics and uterine tissue levels.
    Segui A; Milon D; Cormier M; Lepesant G
    Eur J Drug Metab Pharmacokinet; 1987; 12(3):153-60. PubMed ID: 3436337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side-effects due to the intravenous infusion of erythromycin lactobionate.
    Putzi R; Blaser J; Lüthy R; Wehrli R; Siegenthaler W
    Infection; 1983; 11(3):161-3. PubMed ID: 6885176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia.
    Wiesner B; Wilen-Rosenqvist G; Lehtonen L
    Arzneimittelforschung; 1993 Sep; 43(9):1014-7. PubMed ID: 8240450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically significant hearing loss in renal allograft recipients treated with intravenous erythromycin.
    Vasquez EM; Maddux MS; Sanchez J; Pollak R
    Arch Intern Med; 1993 Apr; 153(7):879-82. PubMed ID: 8466379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin.
    Richards RD; Davenport K; McCallum RW
    Am J Gastroenterol; 1993 Feb; 88(2):203-7. PubMed ID: 8424421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical observations with clarithromycin in pediatrics].
    Sekiguchi T; Okamoto T; Ohara K; Nishimori M; Kozan S; Miyazaki M
    Jpn J Antibiot; 1989 Feb; 42(2):411-9. PubMed ID: 2526254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Jet intravenous injection of erythromycin lactobionate. A possible cause of the occurrence of crisis in torsade de pointe].
    Camilleri JF; Deharo JC; Panagidès D; Broin P; Mésana T; Blin D; Mouly-Bandini A; Dubouloz C; Goudard A; Montiès JR
    Ann Cardiol Angeiol (Paris); 1989 Dec; 38(10):657-9. PubMed ID: 2698118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous erythromycin in acute chest infections in critically ill patients.
    Cade JF; Pain MC
    Anaesth Intensive Care; 1979 May; 7(2):143-7. PubMed ID: 507348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Another look at erythromycin.
    Straughan JL
    S Afr Med J; 1978 Apr; 53(14):527-30. PubMed ID: 354037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tolerance and effectiveness of oral erythromycin ethyl succinate, intravenous Lactobionate and erythromycin base in infants and small children].
    Krepler P; Steinwenter A
    Arch Kinderheilkd; 1970 Jan; 180(2):129-50. PubMed ID: 5443953
    [No Abstract]   [Full Text] [Related]  

  • 19. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacodynamics of erythromycin lactobionate during tonsillectomy in children].
    Leuthardt R; Trümpi B; Morger R
    Schweiz Med Wochenschr; 1989 Oct; 119(40):1372-4. PubMed ID: 2799345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.